A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms
Badran BW, Huffman SM, Dancy M, Austelle CW, Bikson M, Kautz SA, George MS
Bioelectronic Medicine · 2022
Key finding
Four-weeks of at-home self-administered taVNS (two, one-hour sessions daily, delivered at suprathreshold intensities) was feasible and safe.
- Condition
- Depression
- Stimulation
- taVNS
- Evidence tier
- Randomised Controlled Trial
- Participants
- —
Cite this study
Badran, B. W., Huffman, S. M., Dancy, M., Austelle, C. W., Bikson, M., Kautz, S. A., & George, M. S. (2022). A pilot randomized controlled trial of supervised, at-home, self-administered transcutaneous auricular vagus nerve stimulation (taVNS) to manage long COVID symptoms. Bioelectronic Medicine, 8(1). https://doi.org/10.1186/s42234-022-00094-y
Related studies in Depression
Long-term efficacy and safety of vagus nerve stimulation in treatment-resistant depression: A systematic review
Rosson et al. · Journal of Affective Disorders · 2026 · Systematic Review / Meta-Analysis
The efficacy and safety of transcutaneous auricular vagus nerve stimulation in the treatment of depressive disorder: a systematic review and meta-analysis of randomized controlled trials
Tan et al. · Journal of Affective Disorders · 2023 · Systematic Review / Meta-Analysis
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang et al. · The Psychiatric quarterly · 2020 · Systematic Review / Meta-Analysis
Vagus Nerve Stimulation for Depression: A Systematic Review
Lv et al. · Frontiers in psychology · 2019 · Systematic Review / Meta-Analysis
Summary by Vagus Research. Always consult the primary source for the authoritative record.